AbbVie (NYSE: ABBV) announced robust revenue growth for the third quarter, fuelled by the outstanding results of its immunology blockbusters Rinvoq and Skyrizi. Significant costs from acquired research and development caused earnings per share to plummet despite the sales surge.
With third-quarter net revenues of $15.776 billion, the business recorded a 9.1% reported growth in net revenues (8.4% operational). The expansion shows how well AbbVie has moved away from its flagship medication, Humira.
However, pipeline acquisition costs had a significant effect on the bottom line. GAAP diluted EPS decreased by 88.6% to $0.10. The business said that acquired in-process research and development (IPR&D) and milestone expenses had an adverse impact of $1.50 per share, contributing to the 38.0% decline in adjusted diluted EPS to $1.86.
Read More: Gilead Announces 2025 Q3 Results; Lifts EPS Guidance as Strong HIV Sales and Other Revenue Drive
Portfolio Performance Highlights
The company’s more recent immunology medications, which are effectively counteracting Humira’s anticipated fall, were the main driver of its expansion.
Immunology Portfolio
- Net revenues increased 11.9% to $7.885 billion worldwide.
- Sales of Skyrizi jumped 46.8% to $4.708 billion.
- Sales of Rinvoq increased by 35.3% to $2.184 billion.
- Due to ongoing competition from biosimilars, Humira’s sales fell 55.4% to $993 million.
Neuroscience Portfolio
- The revenue for Botox Therapeutic was $985 million.
- Revenue for Vraylar was $934 million.
- Combined sales of Qulipta and Ubrelvy came to $642 million.
GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer
GSK’s risvutatug rezetecan has officially secured Orphan Drug Designation from Japan’s MHLW for the treatment of small-cell lung cancer (SCLC). Supported by durable response data […]
Updated 2025 Guidance and Dividend Increase
AbbVie increased its full-year 2025 adjusted diluted earnings per share guidance due to the robust underlying business performance.
From its earlier prediction of $10.38 to $10.58, the business now anticipates adjusted diluted EPS to be between $10.61 and $10.65. A $2.05 per share year-to-date negative impact on IPR&D and milestones expenses is included in this new guidance.
AbbVie also declared a 5.5% rise to its 2026 dividend, which will start with the dividend due in February 2026, demonstrating confidence in its future.
Last Modified:
